BryantL.M., ChristopherD.M., GilesA.R., et al. (2013). Lessons learned from the clinical development and market authorization of Glybera. Hum. Gene Ther. Clin. Dev., 24, 55–64.
3.
ChowdhuryJ.R., GrossmanM., GuptaS., et al. (1991). Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science, 254, 1802–1805.
4.
CrystalR.G., McElvaneyN.G., RosenfeldM.A., et al. (1994). Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet., 8, 42–51.
5.
De RosaL., CarulliS., CocchiarellaF., et al. (2014). Long-term stability and safety of transgenic cultured epidermal stem cells in gene therapy of junctional epidermolysis bullosa. Stem Cell Reports, 2, 1–8.
6.
DrummM.L., PopeH.A., CliffW.H., et al. (1990). Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell, 62, 1227–1233.
7.
FisherK.J., JoossK., AlstonJ., et al. (1997). Recombinant adeno-associated virus for muscle-directed gene therapy. Nat. Med., 3, 306–312.
8.
FoustK.D., WangX., McGovernV.L., et al. (2010). Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol., 28, 271–274.
9.
GaoG.P., YangY., and WilsonJ.M. (1996). Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol., 70, 8934–8943.
10.
GaoG.P., AlviraM.R., WangL., et al. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A., 99, 11854–11859.
11.
GaoG., AlviraM.R., SomanathanS., et al. (2003). Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc. Natl. Acad. Sci. U.S.A., 100, 6081–6086.
12.
GaoG., VandenbergheL.H., AlviraM.R., et al. (2004). Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol., 78, 6381–6388.
13.
GrossmanM., RaderD.J., MullerD.W., et al. (1995). A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat. Med., 1, 1148–1154.
14.
KesslerP.D., PodsakoffG.M., ChenX., et al. (1996). Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad Sci. U.S.A., 93, 14082–14087.
15.
MulliganR.C., BergP. (1980). Expression of a bacterial gene in mammalian cells. Science, 209, 1422–1427.
16.
NathwaniA.C., TuddenhamE.G., RangarajanS., RosalesC., et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med, 365, 2357–2365.
17.
RaperS.E., YudkoffM., ChirmuleN., et al. (2002). A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum. Gene Ther., 13, 163–175.
18.
RaperS.E., ChirmuleN, LeeF.S., et al. (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab., 80, 148–158.
19.
RosenfeldM.A., SiegfriedW., YoshimuraK., et al. (1991). Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science, 252, 431–434.
20.
RoyS., VandenbergheL.H., KryazhimskiyS., et al. (2009). Isolation and characterization of adenoviruses persistently shed from the gastrointestinal tract of non-human primates. PLoS Pathog., 5, e1000503.
21.
RoyS., Medina-JaszekA., WilsonM.J., et al. (2011). Creation of a panel of vectors based on ape adenovirus isolates. J. Gene Med., 13, 17–25.
22.
SamulskiR.J., ChangL.S., and ShenkT. (1987). A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J. Virol., 61, 3096–3101.
23.
SondhiD., PetersonD.A., EdelsteinA.M., et al. (2008). Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis. Exp. Neurol., 213, 18–27.
24.
StarzlT.E., BilheimerD.W., BahnsonH.T., et al. (1984). Heart-liver transplantation in a patient with familial hypercholesterolaemia. Lancet, 1, 1382–1383.
25.
WilsonJ.M. (2009). Medicine. A history lesson for stem cells. Science, 324, 727–728.
26.
WilsonJ.M., TarrG.E., MahoneyW.C., and KelleyW.N. (1982). Human hypoxanthine-guanine phosphoribosyltransferase. Complete amino acid sequence of the erythrocyte enzyme. J. Biol. Chem., 257, 10978–10985.
27.
WilsonJ.M., YoungA.B., and KelleyW.N. (1983). Hypoxanthine-guanine phosphoribosyltransferase deficiency. The molecular basis of the clinical syndromes. N. Engl. J. Med., 309, 900–910.
28.
WilsonJ.M., JohnstonD.E., JeffersonD.M., and MulliganR.C. (1988). Correction of the genetic defect in hepatocytes from the Watanabe heritable hyperlipidemic rabbit. Proc. Natl. Acad. Sci. U.S.A., 85, 4421–4425.
29.
XiaoX., LiJ., and SamulskiR.J. (1996). Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol., 70, 8098–8108.
30.
XiaoW., ChirmuleN., BertaS.C., et al. (1999). Gene therapy vectors based on adeno-associated virus type 1. J. Virol., 73, 3994–4003.
31.
YangY., NunesF.A., BerencsiK., et al. (1994). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U.S.A., 91, 4407–4411.
32.
ZabnerJ., CoutureL.A., GregoryR.J., et al. (1993). Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell, 75, 207–216.
33.
ZseboK., YaroshinskyA., RudyJ.J., et al. (2014). Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ. Res., 114, 101–108.
34.
ZuckermanJ.B., RobinsonC.B., McCoyK.S., et al. (1999). A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum. Gene Ther., 10, 2973–2985.
